Rani Therapeutics Holdings, Inc.

NASDAQ:RANI

Biotechnology

Healthcare
$0.80 -5.22%

-$0.04 today

Market cap
$52.19M
Beta
0.76
P/E (TTM)
-4.6
EPS (TTM)
-$0.16
52W Low $0.39High $3.87

Volume 0.23M

Average 1.15M

RANI Accounts Receivables

Cash effect of the change in amounts owed by customers; growing receivables consume cash.

Rani Therapeutics Holdings, Inc.NASDAQ: RANI

Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026

Accounts receivables turns positive

Q1 FY2026 accounts receivables was $0, compared with -$600K a year earlier. Trailing-twelve-month accounts receivables was -$1.01M.

Context

  • Accounts receivables amounted to 98.8% of revenue in FY2025, up 57.2 pp from a year earlier.
  • Accounts receivables increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly accounts receivables holds near $0 or moves back toward the trailing-twelve-month quarterly average of -$253.5K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0+100.0% QoQ
Last fiscal yearDec 2025
-$1.61M+277.1% YoY
LTMMar 2026
-$1.01M+69.0% YoY
Accounts Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+100.0%——
1 year+277.1%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accounts Receivables history

USD · from the cash flow

Latest · FY2025
(1.61M) USD
Year-over-year change
-277.1%

Accounts Receivables vs competitors

How RANI compares with its peers on the latest reported figures

  • Peers report in different currencies, so accounts receivables is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +69.0% is the 5th highest of 6, against a peer median of +340.0%.
  • Accounts receivables amounts to 32.0% of revenue for RANI, versus a peer median of 32.2%.
RANI Competitors
Accounts Receivables for RANI and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TNXPTonix Pharmaceuticals Holding Corp.LTM Mar 2026$5.65M USD+70.6%—32.2%
SGMOSangamo Therapeutics, Inc.LTM Mar 2026$4.02M USD+18.0%-59.5%11.6%
MISTMilestone Pharmaceuticals Inc.LTM Mar 2026$2.85M USD+7601.5%+15.2%159.7%
MOLNMolecular Partners AGLTM Mar 2026CHF 1.93M CHF+340.0%-73.6%—
RANIRani Therapeutics Holdings, Inc.LTM Mar 2026$1.01M USD+69.0%—32.0%
CRDFCardiff Oncology, Inc.LTM Mar 2026$214K USD+2045.5%—40.8%
IPHAInnate Pharma S.A.FY2025€0 EUR——0.0%
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026$0 USD———
ELTXElicio Therapeutics, Inc.LTM Mar 2026$0 USD———
Peer median (excluding RANI) —+340.0%-59.5%32.2%

Competitors are the stored peer set for RANI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(8.33M)(63.34M)(33.97M)(56.58M)(29.67M)
Depreciation & Amortization497K548K822K1.03M900K
Deferred Income Tax00000
Stock-Based Compensation22.6M15.78M19.01M16.03M11.8M
Change in Working Capital(3.43M)509K(2.14M)(544K)6.96M
Accounts Receivables000(428K)(1.61M)
Inventory00000
Accounts Payables543K163K(595K)711K(1.05M)
Other Working Capital(3.97M)346K(1.55M)(827K)9.62M
Other Non-Cash Items(43.58M)(10K)(34.96M)4.57M(8.7M)
Operating Cash Flow(32.25M)(46.52M)(51.24M)(35.5M)(18.71M)
Capital Expenditures(506K)(1.62M)(1.23M)(268K)(88K)
Acquisitions (Net)0(851K)000
Purchases of Investments0(73.82M)(73.26M)(58.72M)(33.97M)
Sales of Investments03M104.35M77.55M26.75M
Other Investing Activities0851K01.25M278K
Investing Cash Flow(506K)(72.44M)29.86M19.81M(7.03M)
Debt Repayment(2.85M)29.57M0(5M)(20.72M)
Common Stock Issued73.65M317K395K18.63M61.08M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities26K(886K)(162K)(47K)(59K)
Financing Cash Flow77.15M29.01M233K13.59M40.3M
Effect of Forex Changes00000
Net Change in Cash44.4M(89.95M)(21.14M)(2.1M)14.56M
Free Cash Flow(32.75M)(48.13M)(52.47M)(35.76M)(18.8M)

Rani Therapeutics Holdings, Inc.

NASDAQ:RANI

Intrinsic Alpha fair value

Locked

Current Price

$0.80

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.